FDA probes safety of untested peptides amid industry ties in expert panel

The FDA has raised concerns about the safety of injecting untested peptides such as BPC-157 and TB-500. These substances are widely sold online and marketed by wellness clinics for muscle growth, injury recovery, and anti-aging purposes. A review of their safety and effectiveness is scheduled for July. The upcoming review will involve a panel of doctors and pharmacists. Several of these members have financial links to the peptide industry. Dr. Gabriel Alizaidy, one of the panellists, promotes peptides and charges for advice on sourcing them. Dr. Haleem Mohammed also runs clinics that sell peptides and other unapproved treatments.

Bobby Harshbarger, a pharmacist and state senator, is another member with industry connections. This contrasts with previous panels, which consisted of academics and researchers without such ties. Critics, including Kennedy and his allies, have previously accused government panels of conflicts of interest. The FDA oversees more than 30 expert panels advising on drugs, vaccines, and other products. The July review will assess whether these peptides pose risks to public health. The agency’s warning highlights the potential dangers of unregulated peptide injections.